New Research Agreement
PRESS RELEASE
27 June 2022
Genflow Biosciences Plc
("Genflow" or "the Company")
Research Agreement Signed with Magnitude Biosciences Limited
Genflow (LSE: GENF) is pleased to announce it has entered into a research agreement with Magnitude Biosciences Limited ("Magnitude"), a UK-based, specialist biotechnology research organisation that supports drug discovery and product development.
Founded in 2018 as a Durham University spin out, Magnitude provides an automated service to identify health-span extending drugs faster and more cost effectively than current approaches.
Magnitude leverages Artificial Intelligence and uses nematode worms, called C. elegans, for in-vivo testing in aging research, to accelerate early, pre-clinical drug development for biotech and pharmaceutical firms. Its sophisticated 'Magnitude Biosciences Healthspan technology' enables it to monitor large numbers of C. elegans under multiple conditions and effectively assess the impact of compounds on health and longevity.
Magnitude is led by Dr Weinkove who has over 20 years' experience in C. elegans research, deep biological expertise across multiple research areas and a rich track record in the longevity field. Furthermore, he was appointed as the new Chair of the British Society for Research on Ageing in January this year.
The collaboration will accelerate Genflow's future therapeutic developments and puts the Company on track to carry out its research and pre-clinical drug discovery.
Magnitude will commence generating transgenic strains of C. elegans on behalf of Genflow to test the effect of the expression of human variants of the Sirtuin-6 gene mutation found in centenarians (people aged more than 100 years old) on in-vivo function during aging by analysing C. elegans for age-dependent movement decline.
Genflow is a UK-based biotechnology company focused on longevity and the development of therapies to counteract the effects of aging and diseases associated with advanced age.
Dr Eric Leire, Founder and CEO of Genflow , said: "We are very excited with this collaboration which gives us the opportunity to work with a company that has tremendous experience in longevity and has a uniquely skilled team. Through this collaboration, Genflow's future therapeutic developments will be accelerated by Magnitude's innovative technology which has the capacity to significantly expedite product development, supported by sophisticated machine monitoring."
For further information please contact:
|
Genflow Biosciences Plc |
|
|
Dr Eric Leire Chief Executive |
via Tancredi +44 203 434 2330 |
|
Clear Capital Markets Ltd |
|
|
Corporate Broker Jonathan Critchley Keith Swann |
+44 203 869 6086 +44 203 897 0981 |
|
Tancredi Intelligent Communication Media Relations |
|
|
Salamander Davoudi Helen Humphrey Benedetta Negri da Oleggio |
+44 7957 549 906 +44 7449 226 720 +44 7838 029 970 genflowbio@tancredigroup.com |
About Genflow
Genflow is a UK-based biotechnology company established in 2020. The Company is developing gene therapies designed to target the aging process and to reduce and delay the incidence of age-related diseases. This will be done through novel therapeutics targeting aging in humans by using adeno associated virus ("AAV") vectors to deliver copies of the Sirtuin-6 ("SIRT6") gene variant that is found in centenarians into cells.
Its mission is to increase understanding of the factors that control and impact lifespan. Genflow researches, develops, and commercialises therapeutic solutions to lengthen health span, the amount of time we live in good health, creating biological interventions that enable longer and healthier lives. Genflow is dedicated to the development and commercialisation of novel therapeutics targeting aging in dogs and humans. By treating aging, Genflow can contribute to a decrease in healthcare costs and lessen the emotional and societal burden that comes with an aging population.
To learn more visit www.genflowbio.com
About Magnitude
Magnitude is a UK-based specialist Contract Research Organisation (CRO) who help industry and academia progress their research projects via its team of expert scientists, C. elegans services and unique automated imaging technology.
Magnitude was founded in 2018 by a team of the world's leading C. elegans and automated imaging experts who shared the vision of bringing the benefits of this unique research approach to industry, helping to play their part in accelerating the development of new drug therapies and other research advances to improve human and environmental health. Magnitude helps biotechnology companies, pharmaceutical companies, health products companies, manufacturing and anyone else undertaking Research and Development (R&D) who can benefit from its C. elegans health span technology and expertise. Magnitude's key research areas include early preclinical drug discovery projects, microbiome, aging, neurodegeneration and neurodegenerative diseases, environmental toxicity, reproductive toxicity, and C. elegans transgenics.
To learn more visit https://magnitudebiosciences.com/
-Ends-
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 12 minutes ago City of London Investment Group
- 19 minutes ago BioPharma Credit
- 22 minutes ago BioPharma Credit
- 23 minutes ago Diageo
- 28 minutes ago Barr (A.G.)